A full 14 years after founding CRO Clinipace, its longstanding CEO and president Jeff Williams is to step down.
The chief’s role will be handed over to Jason Monteleone, who founded Pivotal Financial Consulting, a consulting firm with a focus on CROs, while Williams moves into an “expanded advisory role” within the board, according to a statement.
“I am extremely proud of what we have built at Clinipace, but the time has come for me to replace myself and it is my pleasure to welcome Jason Monteleone as CEO,” said Williams.
“After seeing him in action as a consultant to Clinipace over the last several months, I am confident he will build successfully on our company’s 14-year history and lead us into its next phase of growth.”
Williams has over the past three years been an acquisitive chief, buying up European CRO Accovion as well as Hong Kong CRO Choice Pharma, Paragon Biomedical, PFC Pharma, Regulus Pharmaceutical and Worldwide Clinical Research.
It now has more than 800 staffers and has completed more than 1,500 clinical trials.
Monteleone added: “I am honored to join Clinipace on the heels of the remarkable accomplishments that Jeff and his organization have achieved. I am confident that the strong foundation he built, and the talented team here, will serve us well as we continue our quest to make Clinipace the leading mid-market CRO.”
By Ben Adams
Source: Fierce Biotech
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
